You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Roche ends tominersen study in manifest Huntington’s disease

Swiss pharma company Roche has announced that it will discontinue dosing in a Phase III study evaluating its investigational candidate tominersen in manifest Huntington’s disease.